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Abstract
Background: Previous studies in the US and Canada, have shown the positive impact of early palliative care
programs for advanced cancer patients on quality of life (QoL) and even survival time. There has been a lack of
similar research in Europe. In order to generalize the findings from the US and Canada research on a larger scale,
similar studies are needed in different countries with different care settings. The aim of this paper is to describe the
research protocol of a randomized controlled trial, situated in Flanders, Belgium, evaluating the effect of systematic
early integration of palliative care in standard oncology care.
Methods/Design: A randomized controlled trial will be conducted as follows: 182 patients with advanced cancer
will be recruited from the departments of Medical Oncology, Digestive Oncology and Thoracic Oncology of the
Ghent University Hospital. The trial will randomize patients to either systematic early integration of palliative care in
standard oncology care or standard oncology care alone. Patients and informal caregivers will be asked to fill out
questionnaires on QoL, mood, illness understanding and satisfaction with care at baseline, 12 weeks and every six
weeks thereafter. Other outcome measures are end-of-life care decisions and overall survival time.
Discussion: This trial will be the first randomized controlled trial in the Belgian health care setting to evaluate the
effect of systematic early integration of palliative care for advanced cancer patients. The results will enable us to
evaluate whether systematic early integration of palliative care has positive effects on QoL, mood and patient
illness-understanding and which components of the intervention contribute to these effects.
Trial registration: Clinicaltrials.gov Identifier: NCT01865396, registered 24th of May, 2013.
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Background
Patients with advanced and incurable cancer typically
suffer from a multitude of severe symptoms, which often
appear to be under-diagnosed. According to a European
multicentre study, symptom intensity is underestimated
in one in ten patients, with variations between cancer
diagnoses [1]. This underestimation can be explained by
a lack of expert knowledge in symptom management,
limited time to tend to patients and a strong orientation
among health care providers towards cure or life-
prolongation rather than quality of life, leading to lack of
therapeutic pertinacity [2]. There is evidence that all
these problems can be tackled by early implementation
of palliative care programs (PCPs) in standard onco-
logical treatment [3–5]. Results from recent randomised
controlled trials (RCTs) have demonstrated a positive
impact on quality of life of PCP. One PCP for advanced
cancer patients, situated in the US, consisted of a
phone-based psycho-educational intervention led by a
palliative care advanced practice-nurse. The RCT study
of this intervention demonstrated positive effects on
quality of life and to lower symptom intensity for cancer
patients living in a rural setting [6]. Another RCT study,
performed in Canada, implemented an intervention that
consisted of a palliative care consultation by a palliative
care physician and a palliative care nurse with advanced
cancer patients with phone-based follow-up and a 24-h
on-call service. Positive effects were reported four
months after baseline for quality of life, symptom sever-
ity and satisfaction with care [7, 8]. Considered as a
landmark study on integration of palliative care is the
RCT study situated in a major university hospital in Bos-
ton, US [4, 9, 10] where the early palliative care inter-
vention consisted of consultations with outpatients with
metastatic non-small-cell lung cancer by a physician
from the palliative care team shortly after diagnosis of
advanced cancer and at least monthly thereafter. Patients
in the palliative care group had significantly higher qual-
ity of life and a longer median survival of 2.8 months
compared with those who received the standard care
alone [4, 10, 11]. These promising results influenced the
American Society of Clinical Oncology (ASCO) to sup-
port the full integration of palliative care as a routine
part of comprehensive cancer care in the United States
[12]. So far, all published results are from studies that
have been conducted in the US and Canada; no results
have been published on studies in Europe. Before it can
become part of general clinical practice, this early pallia-
tive care approach has to be tested in different centres
and most importantly in different countries where stand-
ard oncology care and/or palliative care may be different
from that in the US or Canada.
In Belgium standard oncology care in the hospital is
organised on a multidisciplinary model. At the medical
level, specialists from different disciplines work closely
with each other in diagnosing and treating the patient.
At a paramedical level, many resources are devoted to
ensuring psychosocial support for cancer patients; every
hospital in Belgium with an oncology department has a
psychosocial team available for patients and their family
carers, consisting of a psychologist, a social worker, a
dietician and a nurse specialist. Consultations with the
professional caregivers of these teams are free of charge
and a first consultation is often organized at the start of
treatment. Because of government funding, all hospitals
in Flanders, Belgium have a small palliative care team
(palliative care nurse 0.5 FTE, palliative care physician
0.5 FTE and palliative care psychologist 0.5 FTE for
every 500 hospital beds) available for patients who no
longer receive curative treatment or care at the hospital.
Palliative care teams are not structurally embedded into
the psychosocial team for cancer patients but consulta-
tions with them are also free of charge. Patients are
mostly seen by a palliative care nurse from the palliative
care team [13]. Despite the availability and financial ac-
cessibility of palliative care teams, palliative care profes-
sionals are only involved in the care of about 60 % of
patients with advanced cancer and they are often in-
volved late in the disease trajectory of these patients
[14], hence a programme which focuses on systematic-
ally providing palliative care early in the disease trajec-
tory of advanced cancer patients is an innovative
approach for cancer patients in Flanders, Belgium.
The systematic early integration of palliative care
(IPaC) study is the first RCT study on early palliative
care for advanced cancer patients to be conducted in the
Belgian health care setting. The overall aim of the
present paper is to describe the IPaC study protocol.
Methods
Study design
This is a phase III randomized controlled trial (RCT) in
a hospital setting with advanced cancer patients receiv-
ing systematic early integration of palliative care with
standard oncology care versus advanced cancer patients
receiving standard oncology care alone. Study partici-
pants will be randomized in a 1:1 fashion to the inter-
vention arm or standard care arm. Patients will be
recruited from the Digestive Oncology, Thoracic Oncol-
ogy and Medical Oncology departments of the Ghent
University Hospital, the second largest hospital in
Belgium. These departments have been selected for the
trial because almost all cancer patients in the Ghent
University Hospital are treated in these departments.
Stratification will take place for the treating oncology de-
partment (Digestive Oncology, Thoracic Oncology and
Medical Oncology) in order to prevent imbalances
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between groups in factors related to possible differences
in standard care [15].
Study participants
One hundred and eighty two patients with advanced
cancer will be recruited by the treating oncologists.
Table 1 describes the inclusion and exclusion criteria.
Additionally, participants are given the possibility of
identifying an important person in their life, either a
relative or friend, to be involved in the study as an infor-
mal caregiver. The informal caregivers of patients who
are randomised to the intervention group may also at-
tend the consultations and hence frequently meet with
the palliative care team as opposed to the informal care-
givers of the participants in standard care. Table 2 de-
scribes the inclusion-criteria for the family carers.
Data collection
Oncologists will describe the study to the eligible patients
with the help of a data manager. The oncologists are asked
to use the terms ‘palliative care’ and ‘palliative care team’
specifically while explaining the study, in order for the pa-
tient to be thoroughly informed and to avoid confusion
when they receive the first visit from the palliative care
team. The oncologists will obtain the patient’s written in-
formed consent prior to enrolment. Our researchers will
inform the informal caregiver of the patients and obtain
written informed consent from them. Study participants
will be randomized in a 1:1 fashion to the standard care
arm or the intervention arm.
The intervention
The intervention, primarily led by the palliative care
nurse, will consist of four major components: the pallia-
tive care consultation, assessment, referring role and
training.
Palliative care consultation
The intervention consists of systematic consultations
with the palliative care nurses of the palliative care team
of the Ghent University Hospital shortly after diagnosis
of advanced cancer or of the progression of the disease.
The palliative care team of the Ghent University Hos-
pital consists of three palliative care nurses (2.5FTE), a
palliative care psychologist (0.5FTE) and a palliative care
physician (0.5FTE). This systematic early integration of
palliative care will be in contrast to standard oncology
care, where referral to palliative care is only at the re-
quest of physicians, nurses or patients and mostly occurs
late in the disease trajectory. The participant receiving
systematic early palliative care will meet with the pallia-
tive care nurses at least once a month and more if
needed or requested by the patient. The palliative care
physician will support and advise the palliative care
nurses and will have at least one consultation every
three months with the participant. All consultations will
take place at a time when the patient is at the hospital
for diagnostic or therapeutic reasons. The content of the
palliative care consultations will be based on the holistic
approach of palliative care and will focus on illness un-
derstanding and illness perception, symptom burden,
psychological coping, spiritual coping and medical deci-
sion making by the patient and his or her informal
caregiver.
Assessment
An interview form (see Additional file 1: Appendix 1)
has been developed to aid in the structuring of each
consultation and allows for an individual approach with
the patient as well as the informal caregiver [4]. The aim
of the members of the palliative care team is to compre-
hensively assess how the patient and informal caregiver
present with regard to illness understanding and illness
perception, symptom burden, psychological coping, spir-
itual coping and medical decision-making at every con-
sultation. However, when a participant is not willing to
Table 1 Inclusion and exclusion criteria for the patient
Inclusion-criteria 1. Patients with a solid tumour treated at the Medical Oncology department, Thoracic Oncology department or Digestive
Oncology department of the Ghent University Hospital
2. Patients within 12 weeks of a new diagnosis of illness progression or patients originating from another hospital who
are within 12 weeks of receiving first-line treatment
3. Patients with a life expectancy of approximately one year (assessed by the treating oncologist)
4. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
5. Patients with the ability to read and respond to questions in Dutch.
Exclusion-criteria 1. Patients under 18 years old
2. Patients with impaired cognition
3. Patients with more than one palliative care consultation since the onset of the disease
4. Patients with one palliative care consultation in the six months before inclusion
Table 2 Inclusion criteria for the family carer
1. This person should either live with the patient or have in-person contact
with him or her at least twice a week.
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discuss a specific topic, this will be respected. For symp-
tom burden, assessment will not only be performed
through personal inquiry based on the time allocation
form but also through the use of the Edmonton Symp-
tom Assessment Scale (ESAS) [16]. The different items
of the ESAS will be filled out by the patient and will be
discussed with the member of the palliative care team.
The palliative care nurse or palliative care physician and
the patient will systematically consider the previous item
scores of the ESAS by using a graph that plots the evolu-
tion of the scores. This will provide an overview of the
fluctuation of the symptoms over time [16].The palliative
care team will report the amount of time spent on these
different topics on the interview form.
Referring role
Because of their holistic approach to care of the patient,
the members of the palliative care team will have an im-
portant role in reporting problems that arise during the
consultation e.g. debilitating side effects of treatment to
the oncology team and other health care professionals
involved inside and outside the hospital. To encourage
this referring role, the intervention will include regular
communication between the members of the palliative
care team and other professional caregivers 1) through
weekly multidisciplinary meetings with the oncology
team; 2) through weekly internal meetings with all the
other members of the palliative care team and 3)
through reporting in the electronic patient file and the
palliative care team is required to complete a referral
checklist at the end of every consultation [Additional file
2: Appendix 2] which includes an assessment of the need
to contact other professional caregivers such as members
of the oncology team, the psychologist, the general practi-
tioner and the home palliative care services.
Training
Several information sessions will be organized for the
members of the palliative care team on specific early
cancer treatments and their possible side effects. The se-
nior oncologists of each department will give a presenta-
tion with the focus on cancer etiology, cancer treatment
(chemotherapy, radiotherapy, etc.), specific symptoms
and side effects and an additional information session
will be organized by the researchers on the implementa-
tion of the intervention, with topics such as the use and
interpretation of the ESAS, the use of the interview form
and the referral checklist.
Standard care
In addition to medical treatment, all patients with ad-
vanced cancer treated in the Ghent University Hospital
receive extensive standard paramedical care. (1) A clin-
ical oncology nurse specialist supports the patients
throughout their disease trajectory by providing infor-
mation on treatment and possible side effects and coor-
dinates hospital appointments. This nurse is available
during hospital visits and can be telephoned during
working hours. (2) An oncology psychologist helps pa-
tients and informal caregivers to cope with the psycho-
social implications of cancer and cancer treatment and
provides further consultations for the patient and/or
their family members at the request of the patient. (3) A
dietician has a standard introductory consultation with
cancer patients diagnosed with oesophageal cancer,
stomach cancer, pancreatic cancer and head and neck
cancers. All other cancer patients are screened for
weight loss during their hospital stay or treatment and
whenever significant weight loss is found, the dietician is
consulted. (4) The social worker helps and supports pa-
tients and their relatives in dealing with the conse-
quences of the disease and treatment in their everyday
life. They make practical arrangements related to the
organization of specific assistance at home and they pro-
vide information about financing, social security, insur-
ance and transitions to residential care. The social
worker attends at the request of the patient, the oncolo-
gist or the oncology nurse. (5) In routine clinical practice
in the Ghent University Hospital, the members of the
palliative care team are not structurally involved in the
treatment trajectory of the cancer patient but at the re-
quest of the patient or at the discretion of the attending
physicians, or a member of the paramedical team in
cases of difficult symptom control and issues related to
end-of-life care, such as advance directives. This referral
mostly occurs late in the treatment trajectory.
Outcome measures
Study objectives
The primary objective of this study is to assess the im-
pact of this intervention’s systematic early integration of
palliative care on the patient’s quality of life. The second-
ary objectives are (1) to assess the impact on the patient’s
median survival time, mood and illness understanding, (2)
the impact on informal caregivers’ quality of life, mood, ill-
ness understanding and satisfaction with care during treat-
ment and after the death of the patient and (3) to examine
whether systematic early integration of palliative care,
alongside hospital treatment and treatment characteristics,
influences advance care planning and end-of-life decision-
making.
Measurement instruments
The socio-demographic and clinical characteristics of
the patient will be collected at baseline by using ques-
tionnaires for the patient and the physician and by con-
sulting the medical record.
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Patient and informal caregiver questionnaires Quality
of life of the patient will be measured with the use of the
European Organisation for Research and Treatment of
Cancer Quality of Life Questionnaire (EORTC QLQ C30)
and the McGill Quality of Life Questionnaire (MQOL)
[17–19]. The MQOL has been selected because it ad-
dresses the existential aspects of quality of life as well as
the physical, emotional and social aspects of quality of life.
A recent review qualified both its content and construct
validity as high [20]. The mood of the patient will be mea-
sured by two instruments: the Hospital Anxiety and
Depression Scale (HADS) and the Patient Health Ques-
tionnaire 9 (PHQ-9) [21–24]. Illness-understanding will
be measured by a forward-backward translation of the
questionnaire developed by the researchers of the previ-
ously mentioned study of palliative care for patients with
metastatic non-small-cell lung cancer [4]. Data on mood,
quality of life, illness understanding and satisfaction with
care of the informal caregivers will be obtained by self-
assessment instruments: HADS, PHQ-9, the Short Form-
36 Health Survey (SF-36) a questionnaire for illness
understanding and by the FAMCARE respectively [25]. A
forward-backward translated and tested version of the
FAMCARE will evaluate the satisfaction with care of the
informal caregivers [26].
The surveys filled out by patients and informal care-
givers, their frequency and the timing of completion are
detailed in Table 3. The patient will complete the baseline
questionnaires before randomization and the follow-up
questionnaires with regard to quality of life, mood and
illness-understanding firstly after 12 weeks and thereafter
every six weeks. Change from baseline to 12 weeks after
inclusion is chosen because approximately 80 % of patients
are expected to be alive at 12 weeks after inclusion [4].
The informal caregivers will complete the baseline ques-
tionnaire before randomization and the follow-up ques-
tionnaires firstly after 12 weeks and then every six weeks.
If the patient dies the informal caregiver is asked to fill out
the questionnaire once more 12 weeks after the death.
Oncologist questionnaires In order to collect informa-
tion on advance care planning and the making of end-
of-life decisions (ELDs), the oncologist will be asked to
fill out a validated Dutch questionnaire that has been
used many times before in nationwide ELD-incidence
studies in Flanders, Belgium. In accordance with previ-
ous studies, three main categories of ELDs will be con-
sidered: the withholding or withdrawal of potentially
life-prolonging treatments (non-treatment decisions),
the intensified alleviation of symptoms with a possible
life-shortening effect and the administration or supply of
drugs with the intention of shortening the patient’s life
(physician-assisted death) [27, 28].
Data on outcomes related to treatment characteristics
will be collected from the medical records of the patient,
including survival time, intensity of chemotherapy, hos-
pital admissions and frequency of contact with a psycholo-
gist/dietician/other health care professional. According to
the definitions of Temel et al., patients will be classified as
having had aggressive care if they meet one of the follow-
ing criteria: 1) chemotherapy within 14 days of death, 2)
no palliative care involvement in the last three months of
life, or 3) admission to a palliative care unit three days or
less before death [4].
Statistical analysis and sample size calculation
To compare baseline characteristics and study outcomes
for patients between groups, Fisher’s exact tests, chi-
square tests and the independent-samples t-test or the
non-parametric equivalent Mann–Whitney U will be
used. The effect of early palliative care on the primary out-
come quality of life will be assessed by multivariate regres-
sion analyses adjusting for baseline scores. Survival
analysis, i.e. Kaplan-Meier and a Cox proportional hazards
model, will be used to examine the effect of systematic
early integration of palliative care on the secondary out-
come survival from the time of inclusion adjusting for
demographic and clinical baseline characteristics. With re-
gard to missing data, we will use the conservative
Table 3 Types of patient and informal caregiver questionnaires and frequency and timing of completion
Week
Baseline 12 18 24 … 12 weeks after patient’s death
PATIENT FORMS
EORTC QLQ C30 and MQOL X X X X X
PHQ-9 and HADS X X X X X
Illness-understanding Questionnaire X X X X X
INFORMAL CAREGIVERS FORMS
General Health SF-36 X X X X X X
PHQ-9 and HADS X X X X X X
FAMCARE X X X X X
Illness-understanding Questionnaire X X X X X
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approach of carrying the last observation forward for all
missing data.
To detect a significant and meaningful difference in the
change of the EORTC QLQ-C30 from baseline to
12 weeks, 118 patients are needed. With the proposed
sample size of 59 for the two groups, the study will have a
power of 80 % to yield a statistically significant result. This
computation assumes a mean score difference of 12 and
the common within-group standard deviation is 23.0. A
difference of 10 points on the multi-items scales from 0 to
100 is considered meaningful (50;51). On the basis of the
study on early palliative care in advanced lung cancer pa-
tients, it can be expected that approximately 80 % of the
study participants will still be alive at 12 weeks after inclu-
sion and drop-out for reasons other than death will
amount to 15 % [4]. In other words, an overall drop-out
rate of 35 % is to be expected, accounting for the planned
inclusion of a total of 182 patients in the study.
Ethical considerations
Since the participants in the control group will receive ex-
tensive medical and paramedical care and will not be re-
fused palliative care at their request, it is deemed that this
research design is acceptable. The procedure of inclusion
is organized in such manner that all patients will be in-
formed firstly at inclusion by their treating oncologists and
secondly by the data manager. The treating oncologist will
spend time explaining the aim of palliative care in general
and its specific aim within this study. They will provide an
information sheet and an informed consent document to
the patient. In a second phase, the data manager will have
a consultation of a minimum of half an hour with the pa-
tient to explain the nature and procedure of the study in
depth and to answer any questions participants might
have. The participants will then be asked to give written
informed consent and will be given a guarantee that: 1) the
data will be treated confidentially, 2) the data will be stored
anonymously for analysis later on, 3) study participation
will be on a voluntary basis and withdrawal will be possible
whenever the patient wishes and 4) non-participation or
withdrawing from the study will have no influence on the
future care of the patient. After providing informed con-
sent, all patients will fill out the baseline questionnaires in
the presence of the data manager so they will be able to re-
quest help if necessary. They will also be able to discon-
tinue completing the questionnaire at any moment.
Moreover, if they appear to be distressed as a result of fill-
ing out the questionnaire, psychologists from the oncology
departments will be available to provide counselling.
Approval
Approval for this study was given by the Ethical Com-
mittee of the Ghent University Hospital, Flanders,
Belgium.
Discussion
The IPaC study is the first randomized controlled single
centre phase III trial to implement an early palliative
care approach in standard oncological care in the hos-
pital setting in Belgium for patients with advanced can-
cer. Following a baseline assessment, patients and their
informal caregivers will be randomized to either the
intervention group where systematic early integration of
palliative care will be implemented or to the control
group where care will be provided as usual. Follow-up
measurements allow the detection of differences in the
quality of life, mood and illness understanding between
patients in the intervention group and those in the con-
trol group.
Our systematic early integration of palliative care inter-
vention is based on the original guidelines of the early pal-
liative care intervention that was examined in the study
for non-small lung cell cancer patients but adaptations
have been incorporated to fit the specifics of the Belgian
health care setting [4]. A first adaptation lies in the fact
that the intervention is primarily led by the palliative care
team nurses and not by the palliative care physician, due
to the organizational structure of hospital-based palliative
care in Flanders. The influence of a nurse-led intervention
may appear to be less effective than a physician-led inter-
vention but it may be less costly and financially more feas-
ible [5]. A second adaptation is that the palliative care
nurse leading the intervention also has a referring role.
The medical and paramedical members of the oncology
team may be able to fulfill the palliative care needs of the
patient adequately but their goal often remains to prolong
life. Palliative care embraces a different approach, focusing
on the needs and expectations of the patient from a holis-
tic point of view, which may lead to the eliciting of differ-
ent information from the patient and the palliative care
nurses who, in this trial, have an important role in refer-
ring this information to the oncology team. This interdis-
ciplinary approach will broaden the view on care. A third
adaptation consists of the semi-systematic format of con-
sultations based on an interview form in which the im-
portant palliative care topics that have to be discussed and
treated are listed. In addition, standard symptom assess-
ment (ESAS) is incorporated to evaluate symptom inten-
sity at each consultation and to provide an overview of the
fluctuation of symptoms. Research has shown that most
health care professionals agree that use of the ESAS en-
hances patient care because it helps patients in articulating
their symptom issues and aids in following them up [29].
Several limitations exist with regards to the IPaC-
study. It is a single-centre study in a tertiary hospital set-
ting, which might limit the generalization of the results
to other hospitals. On the other hand, the organization
of the oncology departments and palliative care team are
similar between hospitals in Belgium, having been
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developed on the basis of the same legislative initiatives.
A second limitation is that participants and staff mem-
bers are not blinded for allocation to the intervention
group or control group. It is possible that the treating
oncologists and other members of the oncology team
are affected by the new approach and will implement
the new insights with patients in the control group
(crossover effect). However, the oncologists and other
health care professionals of the oncology team will be
well informed about the goals and design of the study
and will be made aware of bias risks. A third limitation
concerns the possibility of selection bias, since partici-
pants are asked for consent prior to enrollment. Partici-
pants more open to end-of-life discussions might be
more prone to taking part in the trial than others.
This trial also has several strengths. Firstly, our study
protocol consists of a detailed description of standard on-
cology care, which has a particular focus on providing psy-
chosocial support for cancer patients and their caregivers.
Such a description is needed since the organization of
standard care has an important influence on this interven-
tion, specifically on the referring role of the palliative care
nurses. The inclusion of this explicit description demon-
strates a different approach from other early palliative care
RCTs. Extensive information has been provided regarding
the functioning of the palliative care clinic and the roles of
the palliative care clinician in these trials but little infor-
mation is available concerning the organization of stand-
ard oncology care [4, 6–8, 30–32]. In the US, a broad
range of supportive services are offered by a multidiscip-
linary cohort of oncology health professionals but the
availability of these services varies greatly among institu-
tions. Hence, extrapolation of this information to the
organization of the standard care of the early palliative
care trials situated in the US is not feasible [33]. Secondly,
for our primary outcome measure we have selected a
questionnaire (EORTC QLQ-C30) on quality of life which
is used in clinical trials in Europe and has been studied in-
tensively from the perspective of the clinical significance
of scores [34].
One of the challenges of the trial is the recruitment of
patients with advanced cancer early in the stage of the
disease trajectory. A systematic review of early integra-
tion of palliative care in hospitals has shown that staff-
specific barriers often occur due to the reluctance of
physicians to communicate prognostic information to
the patient and family and the perception by staff of PC
as ‘terminal care’ [35]. Clinicians are often concerned
that referral to PC will alarm patients and their informal
caregivers [5]. Hence, introducing a clinical trial of PC
to advanced cancer patients early in their disease trajec-
tory may prove to be difficult. However, with the support
of the head oncologist of each department and the dis-
seminating of the results of previous research in early
palliative care we expect that the trial will be successfully
initiated in the different departments involved.
Conclusion
The IPaC trial is a randomized controlled trial approved
by the Ethical Committee that aims to assess whether
the quality of life of patients with advanced cancer and
their informal caregivers is enhanced by implementing
systematic early integration of palliative care in a setting
where multidisciplinary cancer care is part of standard on-
cology care. This trial will add to the evidence about the
effectiveness of integrated palliative care programmes for
cancer patients. We hope that this study will not only
show whether systematic early integration of palliative
care is effective for cancer patients in Belgium but will also
provide an increased understanding of the contribution of
the different components of the systematic early integra-
tion of palliative care intervention to their quality of life.
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